WO2007065016A3 - Methods and compositions to improve activity and reduce toxicity of stents - Google Patents

Methods and compositions to improve activity and reduce toxicity of stents Download PDF

Info

Publication number
WO2007065016A3
WO2007065016A3 PCT/US2006/046296 US2006046296W WO2007065016A3 WO 2007065016 A3 WO2007065016 A3 WO 2007065016A3 US 2006046296 W US2006046296 W US 2006046296W WO 2007065016 A3 WO2007065016 A3 WO 2007065016A3
Authority
WO
WIPO (PCT)
Prior art keywords
drug
modulators
administered
beneficial
stents
Prior art date
Application number
PCT/US2006/046296
Other languages
French (fr)
Other versions
WO2007065016A2 (en
Inventor
Jessie L S Au
Guillaume M Wientjes
Original Assignee
Jessie L S Au
Guillaume M Wientjes
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Jessie L S Au, Guillaume M Wientjes filed Critical Jessie L S Au
Publication of WO2007065016A2 publication Critical patent/WO2007065016A2/en
Publication of WO2007065016A3 publication Critical patent/WO2007065016A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L31/00—Materials for other surgical articles, e.g. stents, stent-grafts, shunts, surgical drapes, guide wires, materials for adhesion prevention, occluding devices, surgical gloves, tissue fixation devices
    • A61L31/14—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
    • A61L31/16—Biologically active materials, e.g. therapeutic substances
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
    • A61L2300/40—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a specific therapeutic activity or mode of action
    • A61L2300/412—Tissue-regenerating or healing or proliferative agents
    • A61L2300/414—Growth factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
    • A61L2300/40—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a specific therapeutic activity or mode of action
    • A61L2300/432—Inhibitors, antagonists
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
    • A61L2300/60—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a special physical form
    • A61L2300/62—Encapsulated active agents, e.g. emulsified droplets
    • A61L2300/624—Nanocapsules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
    • A61L2300/60—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a special physical form
    • A61L2300/62—Encapsulated active agents, e.g. emulsified droplets
    • A61L2300/626—Liposomes, micelles, vesicles

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Surgery (AREA)
  • Vascular Medicine (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Materials For Medical Uses (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Disclosed is a method of improving the efficacy of endovascular drug- releasing stents implanted in a subject, wherein one or more modulators of drug transport are administered at such a time as is beneficial to maintain nearby tissue concentrations of the drug released by the stent within their therapeutically effective range, wherein one or more modulators of drug activity are administered at such a time as is beneficial to prevent restenosis, and wherein one or more modulators of drug activity are administered at such a time as is beneficial to promote the early healing or reendothelialization process.
PCT/US2006/046296 2005-12-02 2006-12-04 Methods and compositions to improve activity and reduce toxicity of stents WO2007065016A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US74185505P 2005-12-02 2005-12-02
US60/741,855 2005-12-02

Publications (2)

Publication Number Publication Date
WO2007065016A2 WO2007065016A2 (en) 2007-06-07
WO2007065016A3 true WO2007065016A3 (en) 2009-01-08

Family

ID=38092899

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2006/046296 WO2007065016A2 (en) 2005-12-02 2006-12-04 Methods and compositions to improve activity and reduce toxicity of stents

Country Status (1)

Country Link
WO (1) WO2007065016A2 (en)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2200613B1 (en) 2007-09-21 2018-09-05 The Johns Hopkins University Phenazine derivatives and uses thereof
CN101161300B (en) 2007-11-27 2011-03-16 北京美中双和医疗器械有限公司 Arsenic trioxide medicament elution bracket and its preparation method
CN103054810A (en) * 2011-12-31 2013-04-24 苏州雷纳药物研发有限公司 High encapsulation rate curcumin albumin nano pharmaceutical composition
WO2014152207A1 (en) 2013-03-15 2014-09-25 Mylan Laboratories, Inc. Hot melt granulation formulations of poorly water-soluble active agents
CN106754705B (en) * 2017-02-09 2020-01-31 广州市鲁诚生物科技有限公司 NK cell culture medium and method for in-vitro amplification of NK cells
CN108186574B (en) * 2018-03-01 2019-08-27 燕山大学 A kind of triptolide liposome and preparation method thereof of platinum-gold nano ball shell cladding
CN108484751B (en) * 2018-04-19 2020-06-23 西南大学 Nobiletin antigen and preparation method and application thereof
CN108670977A (en) * 2018-07-23 2018-10-19 广西大学 A kind of drug inhibiting tumor cell proliferation

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030040790A1 (en) * 1998-04-15 2003-02-27 Furst Joseph G. Stent coating
WO2003026574A2 (en) * 2001-09-24 2003-04-03 Au Jessie L-S Methods and compositions to determine the chemosensitizing dose of suramin used in combination therapy
US20030083646A1 (en) * 2000-12-22 2003-05-01 Avantec Vascular Corporation Apparatus and methods for variably controlled substance delivery from implanted prostheses
US6599912B1 (en) * 1999-06-03 2003-07-29 Jessie L. -S. Au Methods and compositions for modulating cell proliferation and cell death
US6663880B1 (en) * 2001-11-30 2003-12-16 Advanced Cardiovascular Systems, Inc. Permeabilizing reagents to increase drug delivery and a method of local delivery
US20050002865A1 (en) * 1996-10-28 2005-01-06 Amersham Health As Diagnostic/therapeutic agents
US20050010170A1 (en) * 2004-02-11 2005-01-13 Shanley John F Implantable medical device with beneficial agent concentration gradient

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050002865A1 (en) * 1996-10-28 2005-01-06 Amersham Health As Diagnostic/therapeutic agents
US20030040790A1 (en) * 1998-04-15 2003-02-27 Furst Joseph G. Stent coating
US6599912B1 (en) * 1999-06-03 2003-07-29 Jessie L. -S. Au Methods and compositions for modulating cell proliferation and cell death
US20030083646A1 (en) * 2000-12-22 2003-05-01 Avantec Vascular Corporation Apparatus and methods for variably controlled substance delivery from implanted prostheses
WO2003026574A2 (en) * 2001-09-24 2003-04-03 Au Jessie L-S Methods and compositions to determine the chemosensitizing dose of suramin used in combination therapy
US6663880B1 (en) * 2001-11-30 2003-12-16 Advanced Cardiovascular Systems, Inc. Permeabilizing reagents to increase drug delivery and a method of local delivery
US20050010170A1 (en) * 2004-02-11 2005-01-13 Shanley John F Implantable medical device with beneficial agent concentration gradient

Also Published As

Publication number Publication date
WO2007065016A2 (en) 2007-06-07

Similar Documents

Publication Publication Date Title
WO2007065016A3 (en) Methods and compositions to improve activity and reduce toxicity of stents
WO2010003076A3 (en) Controlled and localized release of retinoids to improve neointimal hyperplasia
TW200603838A (en) Extended release biodegradable ocular implants
WO2007106554A3 (en) Treatment and prevention of vascular hyperplasia using polyamine and polyamine analog compounds
MX2007002688A (en) Device for the delivery of bioactive agents and a method of manufacture.
WO2004069201A3 (en) Compounds useful in coating stents to prevent and treat stenosis and restenosis
WO2008057344A3 (en) Coated surgical mesh
WO2005076979A3 (en) Diagnosis and therapeutics for cancer
WO2008024626A3 (en) Bioresorbable stent with extended in vivo release of anti-restenotic agent
DE60330144D1 (en) COATING OF STENTS WITH DELAYED ACTIVE INGREDIENT EXTRACTION
WO2001047572A3 (en) Device and active component for inhibiting formation of thrombus-inflammatory cell matrix
WO2007047919A3 (en) Treatment of restenosis and stenosis with dasatinib
MXPA05010899A (en) Aminopyrimidine derivatives and their medical use.
DE602005013793D1 (en) THIAZONE DERIVATIVES WITH VAP-1-HEMMENDER EFFECT
WO2003009777A3 (en) Delivery of therapeutic capable agents
WO2009076170A3 (en) Combinations of therapeutic agents for treating cancer
WO2007137298A3 (en) Systems and methods for delivering a rapamycin analog that do not inhibit human coronary artery endothelial cell migration
WO2006104894A3 (en) Coating for implantable devices and a method of forming the same
WO2007150018A3 (en) Steroid-containing sustained release intraocular implants and related methods
EP2114303A4 (en) Vascular implants and methods of fabricating the same
DE60130032D1 (en) Device for delivery of therapeutic agents
WO2011079249A3 (en) Vitamin d glycosides and sulfates for treating diseases
CR20230485A (en) Phosphorus derivatives as novel sos1 inhibitors
WO2007137294A3 (en) Dexamethasone-eluting endoprosthesis to promote human coronary artery endothelial cell migration
WO2006138317A3 (en) Dosage regimen for prasugrel

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application
NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 06838960

Country of ref document: EP

Kind code of ref document: A2